In clinical trials
Digestive & weight
Glepaglutide
Evidence
Clinical trials
Class
Long-acting GLP-2 receptor agonist
KEY TAKEAWAY
Glepaglutide is a long-acting GLP-2 analog developed for short bowel syndrome. Glepaglutide is not FDA-approved. The FDA asked for additional trial data after an initial application.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting GLP-2 receptor agonist
Being studied for
Studied in short bowel syndrome
Key fact
Glepaglutide is not FDA-approved. The FDA asked for additional trial data after an initial application.
Route
Subcutaneous injection in trials
Evidence strength
Clinical trials
Glepaglutide is a long-acting GLP-2 analog developed for short bowel syndrome.
It activates GLP-2 receptors to support growth of the intestinal lining and improve absorption of fluid and nutrients.
Glepaglutide is not FDA-approved. The FDA asked for additional trial data after an initial application.
Studied in short bowel syndrome.
Reported effects included abdominal pain, injection-site reactions and swelling.
Glepaglutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.